ArticleOncotarget2013

Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.

Alessia Noto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.